- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03663868
Single-center Prospective Cumulus Cell Test Study in rFSH Patients
September 14, 2018 updated by: Universitair Ziekenhuis Brussel
Cumulus Cell mRNA Analysis as Oocyte Quality Marker in the Fertility Lab in a Prospective Single-center Study for rFSH Stimulated Patients
Performing an additional non-invasive oocyte diagnostic test based on cumulus cell gene expression could improve the outcome of the ART cycle for rFSH stimulated patients
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Inge Van Vaerenbergh, PhD
- Phone Number: +32 2 477 46 45
- Email: inge.vanvaerenbergh@uzbrussel.be
Study Contact Backup
- Name: Tom Adriaenssens, MSc
- Phone Number: +32 2 477 46 45
- Email: tom.adriaenssens@uzbrussel.be
Study Locations
-
-
Brussels
-
Jette, Brussels, Belgium, 1090
- Recruiting
- Universitair Ziekenhuis Brussel
-
Contact:
- Inge Van Vaerenbergh, PhD
- Phone Number: +32 2 477 46 45
- Email: inge.vanvaerenbergh@uzbrussel.be
-
Contact:
- Johan Smitz, Prof. Dr.
- Phone Number: +32 2 477 50 52
- Email: johan.smitz@uzbrussel.be
-
Principal Investigator:
- Inge Van Vaerenbergh, PhD
-
Principal Investigator:
- Tom Adriaenssens, MSc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 38 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- scheduled for intracytoplasmatic sperm injection (ICSI) and single (or double) embryo transfer on day 3
- patients down regulated with gonadotropin-releasing hormone (GnRH) antagonist and stimulated with recombinant Follicle Stimulating Hormone (FSH)
- undergoing first or second IVF or ICSI cycle with transfer
- Body Mass Index (BMI) between 17 and 33
- regular menstrual cycle (between 24 and 35 days)
Exclusion Criteria:
- smokers (> 10 cigarettes per day)
- patients requesting Pre-implantation Genetic Diagnosis (PGD)
- patients with polycystic ovary syndrome (PCOS), or severe endometriosis (AFS stage 3-4)
- couples where the partner has an extremely low sperm count i.e.: extreme oligo-astheno-teratozoospermia (OAT) (< 100.000/ml) or scheduled for testicular sperm extraction (TESE)
- results of eventual preceding cycles may not indicate a known genetic disease, or low ovarian response or an oocyte maturation defect
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CC-Test diagnosis and Day 3 transfer
Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
|
Classification of the oocyte/embryo based on the gene expression pattern observed in the cumulus cells
|
No Intervention: Day 3 transfer control group
Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 3 of embryo growth (cleavage stage embryo)
|
|
No Intervention: Day 5 transfer control group
Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 5 of embryo growth (blastocyst stage embryo)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical pregnancy as observed by ultrasound
Time Frame: 2 months after embryo transfer
|
This observation is routinely performed by the treating physician for every patient undergoing standard ART treatment and is thus available from the fertility center database
|
2 months after embryo transfer
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive beta-hCG pregnancy as observed by serum analysis
Time Frame: 12-17 days after embryo transfer
|
This observation is routinely performed by the treating physician for every patient undergoing standard ART treatment and is thus available from the fertility center database
|
12-17 days after embryo transfer
|
Live birth by questionnaire
Time Frame: at least 9 months after embryo transfer
|
This observation is routinely performed by the study nurses of the fertility center for every patient undergoing standard ART treatment and is thus available from the fertility center database.
This measurement does not include a scale, there is either a child born or not.
The date of delivery and the gender of the child are asked together with eventual complications.
|
at least 9 months after embryo transfer
|
Cumulative pregnancy by ultrasound (for pregnancy follow-up) and questionnaire (for live birth follow-up) (see outcome 1 and 3)
Time Frame: 2 years after embryo transfer
|
This is the compilation of the data gathered in outcome 1 and 3 for eventual consecutive cycles.
This observation is routinely performed by the study nurses of the fertility center for every patient undergoing standard ART treatment and is thus available from the fertility center database
|
2 years after embryo transfer
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Johan Smitz, Prof. Dr., Universitair Ziekenhuis Brussel
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 14, 2018
Primary Completion (Anticipated)
August 1, 2019
Study Completion (Anticipated)
August 1, 2021
Study Registration Dates
First Submitted
September 3, 2018
First Submitted That Met QC Criteria
September 6, 2018
First Posted (Actual)
September 10, 2018
Study Record Updates
Last Update Posted (Actual)
September 18, 2018
Last Update Submitted That Met QC Criteria
September 14, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BUN143201318000 b
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey
Clinical Trials on CC-Test
-
Universitair Ziekenhuis BrusselUnknown
-
Universitair Ziekenhuis BrusselUnknown
-
CelgeneCompleted
-
Radboud University Medical CenterNorgineUnknownColorectal NeoplasmsNetherlands, Greece
-
Juno Therapeutics, Inc., a Bristol-Myers Squibb...Recruiting
-
Bristol-Myers SquibbWithdrawnAdvanced Solid TumorsSpain
-
Celgene CorporationCompletedLeukemia Lymphocytic Chronic B-CellUnited States, Germany
-
CelgeneRecruitingLeukemia, MyeloidUnited States, France, Canada
-
CelgeneActive, not recruitingMultiple MyelomaSpain, Canada, United States
-
CelgeneCompleted